MedTrace Logo

A Phase I Study of HW201877 in Healthy Subjects

NCT07373457 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).

Conditions

  • Healthy Participants
  • IBD (Inflammatory Bowel Disease)

Interventions

DRUG

HW201877 capsules

Dose 1 to Dose 7

DRUG

Placebo

Dose 1 to Dose 7

Sponsors & Collaborators

  • Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-26
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07373457 on ClinicalTrials.gov